A recent study shows that freeze-drying and room temperature biobanking does not affect RNA quality in cultured human cells.
Category: biotech/medical
Lab-grown brain organoids power biocomputers
A feature story authored by Simon Spichak, MSc investigates how biotech companies like Cortical Labs and FinalSpark harness human brain cells to electrodes, performing computational functions and testing the cells’ responses to electrical and chemical stimuli. To create biocomputers, scientists grow organoids—small spheres of, in this case, neural tissue—on top of multi-electrode arrays in a hardware shell, which can then be used for everything from testing medications to playing video games. The work is published in the Journal of Medical Internet Research.
Freeze-dried reagents and hand-powered hardware bring biomanufacturing to remote labs
Researchers at the University of Toronto’s Leslie Dan Faculty of Pharmacy, working with collaborators around the world, have demonstrated the effectiveness of a suite of low-cost, portable biotechnology tools designed to improve access to laboratory research and diagnostics in resource-limited settings.
Published in Science Advances, the study highlights how decentralized biomanufacturing tools and freeze-dried reagents can help researchers produce high-value biological materials locally—reducing reliance on fragile international supply chains and expanding access to life sciences innovation globally.
The research was led by Keith Pardee, associate professor at the Leslie Dan Faculty of Pharmacy, alongside collaborators including Camila González in Bogotá, Colombia, Fernán Federici in Santiago, Chile, and Lindomar Pena in Recife, Brazil.
Unprecedented view inside live stem cells reveals aging process and loss of regenerative capacity
Scientists have developed a powerful new technique that allows them to observe how individual cells manufacture proteins during aging, offering an unprecedented glimpse into the hidden molecular activity of stem cells in living tissue. As a result of the research, conducted at the Institute for Regenerative Medicine in Switzerland, scientists were able to observe aging unfold inside individual epidermal stem cells.
What scientists saw was the intricate choreography within stem cells and how those molecular dance steps slow and change with age. The team of Swiss scientists has concluded that the process of aging reshapes how skin stem cells manufacture proteins. The findings are published in the journal Molecular Cell.
Biohybrid Robots Explained: When Biology Meets Robotics & AI! #BiohybridRobots #SyntheticBiology
/ @lostpagesofscience.
Discover the incredible future of biohybrid robots, the revolutionary fusion of synthetic biology, artificial intelligence, and robotics! In this episode, we explore robots powered by living tissues, capable of self-repair, adaptation, and natural movements. Find out how these bioengineered robots can transform medicine, agriculture, environmental science, and prosthetics. Learn about the ethical considerations, safety challenges, and futuristic possibilities of combining biological materials with robotic systems.
🔔 Don’t forget to subscribe for cutting-edge science & technology content!
📌 Chapters:
00:00 — Introduction to Biohybrid Robots.
01:30 — What Are Biohybrid Robots?
03:50 — How Scientists Build Biohybrid Robots.
06:20 — Medical Applications & Healthcare.
08:45 — Revolutionary Prosthetics.
11:00 — Environmental Biohybrid Robotics.
13:20 — Agricultural Applications.
14:50 — Ethical & Safety Considerations.
17:00 — Future Possibilities.
19:00 — Conclusion & Call to Action.
SEO Keywords:
Biohybrid robots.
Synthetic biology and robotics.
Living robots.
The Startup Freezing Humans For Tomorrow — Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
Join us for a deep-dive conversation with Dr Emil Kendziorra, CEO of Tomorrow.bio, as we explore the cutting edge of cryopreservation and medical biostasis.
Dr Kendziorra, who began his career in cancer research with a summa cum laude degree from the University of Göttingen, shares his remarkable journey from academic science to entrepreneurship, and ultimately to founding Tomorrow.bio — a company he considers his life’s work.
In this interview, he discusses the motivations behind his pivot from traditional longevity research to the frontier of cryomedicine, the operational and emotional lessons learned from cryopreserving over 20 human patients and 10 pets, and his vision for making this technology more accessible in the future.
Tomorrow.bio stands as Europe’s fastest-growing cryopreservation company, with over 800 members across 200+ cities and 45+ countries. The company offers both whole-body cryopreservation and brain-only preservation, using a transparent pricing model designed for long-term value.
With a recent €5 million Seed round and a mission to advance medical biostasis, Emil discusses the unique challenges and opportunities of operating in this space, the ethical considerations of a technology that may not achieve revival for decades, and his long-term vision for the field.
Key Points.
A man with terminal glioblastoma was given 12–15 months to live
After four injections of a therapy called Anktiva, his latest scan came back normal.
The treatment has been studied for more than a decade and has shown promise across multiple cancer types, yet it’s only approved for a narrow form of bladder cancer.
Should potentially life-saving treatments move through the approval process faster for patients with no other options?